{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:36:44Z","timestamp":1775659004471,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["X-1704-393-903"],"award-info":[{"award-number":["X-1704-393-903"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.semarthrit.2022.152019","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T01:48:14Z","timestamp":1651110494000},"page":"152019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study"],"prefix":"10.1016","volume":"55","author":[{"given":"Anna","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-1159","authenticated-orcid":false,"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152019_bib0001","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"19","key":"10.1016\/j.semarthrit.2022.152019_bib0004","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0005","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0007","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0008","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0009","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/rheumatology\/39.7.689","article-title":"Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story","volume":"39","author":"Smolen","year":"2000","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0010","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1759720X11419038","article-title":"The efficacy and safety of tacrolimus in rheumatoid arthritis","volume":"3","author":"Dutta","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/14397595.2017.1332471","article-title":"Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): post-marketing surveillance in Japan","volume":"28","author":"Takeuchi","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0013","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/1756-185X.13521","article-title":"Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate","volume":"22","author":"Shin","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0014","first-page":"799","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea","volume":"46","author":"Cheol-Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0015","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3260","article-title":"Validation of rheumatoid arthritis diagnoses in health care utilization data","volume":"13","author":"Kim","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0016","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12879-017-2198-y","article-title":"Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0018","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jclinepi.2006.07.011","article-title":"Veteran's affairs hospital discharge databases coded serious bacterial infections accurately","volume":"60","author":"Schneeweiss","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0019","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti\u2013tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0020","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0021","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0022","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0023","series-title":"Survival analysis: a self, learning text","author":"Kleinbaum","year":"2012"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0024","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe-Andersen","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.07.006","article-title":"Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients","volume":"88","author":"Park","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0026","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"Bergstra","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0027","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/acr.24038","article-title":"Risk of serious infection among initiators of tumor necrosis factor inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study","volume":"72","author":"Kang","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0028","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1080\/21645515.2019.1603985","article-title":"Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015","volume":"15","author":"Choi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0029","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3899\/jrheum.201248","article-title":"Safety of the methotrexate-leflunomide combination in rheumatoid arthritis: results of a multicentric, registry-based, cohort study (biobadaBrasil)","volume":"48","author":"Bredemeier","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0031","unstructured":"Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea, 2016. Cheongju: Korea Centers for Disease Control and Prevention; 2017."},{"key":"10.1016\/j.semarthrit.2022.152019_bib0032","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/rheumatology\/keaa702","article-title":"Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden","volume":"60","author":"Shin","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0033","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0034","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0035","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2022.152019_bib0036","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:43Z","timestamp":1758733783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":36,"alternative-id":["S0049017222000701"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152019","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152019"}}